Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COPERNICUS: Subcutaneous Amivantamab + Lazertinib or Chemotherapy in EGFR-Mutated NSCLC
NCT06667076Phase 2Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2024
- Primary completion
- May 2029
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 14
01
Overview
A Phase 2 trial of amivantamab in non-small cell lung cancer (NSCLC), sponsored by Janssen Pharmaceutical. Started Dec 2024; status: recruiting.
02
Drugs
amivantamab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06667076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06667076.